Postnatal therapeutics for improving neurodevelopmental outcomes in IUGR

CIs: Wixey, Colditz, Bjorkman (RCHF $56k 2017-20; RBWH $40k 2018-19; NHMRC1147545 $358k 2018-20).

Aims: Assess the ability of ibuprofen and/or stem cells to reduce neuroinflammation in the IUGR brain using current MRI/MRS85.

Mechanism: Anti-inflammatory.

New Knowledge: This pre-clinical study in piglets will explore postnatal treatments targeting inflammation as a way to minimise impairment to brain development.